
BiTE® Immuno-Oncology Platform
Learn about the mechanism of action and the potential promise of the BiTE® immuno-oncology platform.
Amgen is proud to be a part of the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021). While you’re here, you can explore the latest scientific information and disease state education. Additionally, you can learn about Amgen’s long-term commitment to developing and delivering transformative medicines for oncology patients.
Learn about the mechanism of action and the potential promise of the BiTE® immuno-oncology platform.
An immersive and dynamic experience that explores multiple cancer environments and how BiTE® technology can be used with the goal of targeting different tumor types.
Learn more about the DLL3 protein, which is expressed on the surface of many tumor cells.
The latest educational resource on the BiTE® immuno-oncology platform.
PSMA—a clinically validated target in metastatic castration-resistant prostate cancer (mCRPC).
A quick and easily accessible reference for the BiTE® immuno-oncology platform.
A clinical trial program for patients with non-small cell lung cancer (NSCLC) whose cancer has the KRAS G12C mutation.
A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with meaningful effects in serious diseases.
A comprehensive interactive resource for Amgen’s oncology pipeline, including molecules, targets, malignancies, and clinical trials.
Learn more about key clinical trials happening in Amgen oncology.
Learn about the mechanism of action and the potential promise of the BiTE® immuno-oncology platform.